186 related articles for article (PubMed ID: 22669625)
21. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
22. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
Unno M
Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):392-5. PubMed ID: 20203442
[No Abstract] [Full Text] [Related]
23. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
Spiegel AM; Libutti SK
Nat Rev Clin Oncol; 2011 May; 8(5):258-9. PubMed ID: 21448150
[No Abstract] [Full Text] [Related]
24. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib for advanced pancreatic neuroendocrine tumors.
Hubner RA; Valle JW
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
27. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
Faivre S; Ronot M; Dreyer C; Serrate C; Hentic O; Bouattour M; Bruno O; Couvelard A; Vilgrain V; Raymond E
Target Oncol; 2012 Jun; 7(2):127-33. PubMed ID: 22585430
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
29. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
30. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
31. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
32. Progress in the treatment of neuroendocrine tumors.
Chan JA; Kulke MH
Curr Oncol Rep; 2009 May; 11(3):193-9. PubMed ID: 19336011
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic NETs: where do we stand now?
Faivre S; Castellano D; Strosberg J; González E; Salazar R
Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
[TBL] [Abstract][Full Text] [Related]
34. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
Wang W; Jiang CY; Wang HW
J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
[No Abstract] [Full Text] [Related]
35. Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2011 Mar; 12(2):117-9. PubMed ID: 21386634
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Reidy-Lagunes D; Thornton R
Curr Oncol Rep; 2012 Jun; 14(3):249-56. PubMed ID: 22434313
[TBL] [Abstract][Full Text] [Related]
37. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
Mankal P; O'Reilly E
Expert Opin Pharmacother; 2013 Apr; 14(6):783-92. PubMed ID: 23458511
[TBL] [Abstract][Full Text] [Related]
39. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Maxwell JE; Sherman SK; Howe JR
Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
Raymond E; Faivre S; Hammel P; Ruszniewski P
Target Oncol; 2009 Dec; 4(4):253-4. PubMed ID: 19911111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
